The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of lenalidomide (Revlimid) as a maintenance therapy following autologous stem cell transplant (ASCT) for patients with newly diagnosed multiple myeloma, according to Celgene, the manufacturer of the treatment.
“Despite substantial progress made so far in multiple myeloma treatment, it remains an incurable disease. We welcome this CHMP opinion as it confirms the important role that Revlimid plays in treating multiple myeloma, extending the use of Revlimid across the disease continuum. At Celgene, we aspire to turn some of the most challenging diseases, like multiple myeloma, into manageable conditions. Therefore, we will continue to invest more than one-third of our revenues back into research and development," Tuomo Pätsi, president of Celgene in Europe, the Middle East and Africa, said in a statement.
Attal M, Palumbo A, Holstein SA, et al. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS). J Clin Oncol 34, 2016 (suppl; abstr 8001).
... to read the full story